A Special Role of the Group 17,18 Chromosomes in Reticuloendothelial Neoplasia by Spiers, A. S. D. & Baikie, A. G.
77
A SPECIAL ROLE OF THE GROUP 17,18 CHROMOSOMES
IN RETICULOENDOTHELIAL NEOPLASIA
A. S. D. SPIERS* AND A. G. BAIKIE
From the Medical Unit, University College Hospital Medical School, London,
England, and the Department ofMedicine, the University ofTasmania, Hobart,
Tasmania, Australia
Received for publication November 24, 1969
SUMMARY.-The hypothesis is advanced that abnormalities of the chromo-
some group 17,18 play a special role in the genesis and/or evolution of some
reticuloendothelial neoplasms. Aberrations of the group 17,18 chromosomes
in tumour cells exceed in variety the reported anomalies of any other chromo-
some. Both the frequency of these aberrations and their nature make them
most unlikely to be due to chance. They appear to be non-random, often
occurring in every cell ofa tumour, and likethe Ph' anomaly in chronic granulo-
cytic leukaemia, might possess aetiological significance. The Ep- and Eq-
chromosomalanomalies resemble the Ph' inbeing fine structural modifications,
which occur as acquired lesions only in neoplasms, often in tumour cells with
otherwise normal karyotypes.
Aberrations ofthe group 17,18 chromosomes may sometimes be secondary to
neoplasia but nevertheless of evolutionary significance for the tumour cells.
Changes leading to relative or absolute excess oflong-arm material of chromo-
some 18 may confer survival advantage upon cells, particularly if a normal
complement of short-arm material is simultaneously retained. However,
specific deletion ofthe distal part ofthe long arms of No. 18 may also favour cell
survival. The short arms of chromosome 18 may carry genes limiting cell
reproduction, while the long arms carry material promoting proliferation.
Moredistallyonthelongarms,there maybegeneswhich also limit reproduction.
Disturbances affecting the balance between these components of the genome
may be important in inception of neoplasia or subsequent evolution of tumour
cell lines.
GREATLY improved methods for studying human chromosomes have been
available for over a decade and their application to the study of tumour cyto-
genetics has led to a rapid accumulation of information, particularly concerning
the leukaemias. However, with the striking exception of the Philadelphia
chromosome in chronic granulocytic leukaemia (Nowell and Hungerford, 1960a, b;
Baikie et al., 1960), no specific chromosomal lesion has been identified which is
regularly associated with one or more neoplasms. It seems clear that such specific
lesions are uncommon when chromosomes are examined by existing techniques.
On the other hand, evidence is available to indicate whether a spectrum of
different lesions, which all affect a particular chromosome or chromosome group,
has any special association with one or more types of neoplasm. We wish to
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advance the hypothesis that lesions of the chromosomes of the group 17,18 play a
special role in the genesis and/or evolution of neoplasia, particularly in lymphoid
and reticuloendothelial tissues.
A chromosome group may possess a special role in a neoplasm if abnormalities
affecting a member of the group are regularly associated with the tumour in
question, the best example being the near-constant association ofthe Philadelphia
chromosome with chronic granulocytic leukaemia. In other neoplasms no such
clear-cut association exists: thus in acute leukaemia (Berger, 1965; Baikie, 1966)
and in carcinomas (Spriggs, Boddington and Clarke, 1962; Ishihara, Kikuchi and
Sandberg, 1963) a great variety of changes affects many chromosome groups. In
this situation, a chromosome group may still be considered to have some special
role if aberrations of its members are observed more frequently than might occur
by chance. If a group is numerically large, such as group 6-12 of the Denver
classification (Human Chromosomes Study Group, 1960), the chance occurrence
of aberrations in several cases is more likely than if a small group with only 4
member chromosomes is involved. An unusual chromosomal anomaly, such as a
constant structural rearrangement, if found in several cases is more likely to be
significant than the repeated occurrence of a common anomaly, such as a trisomy
or monosomy.
The special role of a chromosome group in neoplasia need not be a causal one.
A recurring anomaly may have causal significance or may be a phenomenon
secondary to the occurrence of neoplasia. In the latter case, the chromosomal
change may be essential to the evolution of the tumour or may be an irrelevant
event without evolutionary significance. Since the induction of tumours is most
likely to be a multi-stage process, the distinction between causal and evolutionary
chromosomal changes may often be an unreal distinction. It is proposed to
review the evidence which suggests that the chromosomes of the group 17,18 may
play a special role in neoplasia: the status of this role, whether primary or secon-
dary, relevant or irrelevant to the natural history of tumours, may then be
assessed.
EXPERIMENTAL EVIDENCE
Fig. 1 sets out schematically the aberrations of the group 17,18 chromosomes
which have been observed in the metaphases of tumour cells studied by various
techniques. The letter " E " has been used as a convenient notation for the
morphologically normal members ofthe group. In the Patau classification (Patau,
1960) the pair 16 was also placed in the E group, but as these chromosomes are
readily distinguished as a separate pair, the use of a 6-member group E, or refer-
ences to " the group 16-18 ", as in some earlier communications, reduces precision
in reporting results. On the other hand, we will not attempt to regularly differen-
tiate the chromosome pairs 17 and 18 from one another. While such differentia-
tion is frequently possible in preparations of optimal quality, the morphology of
chromosomes prepared from tumour tissue is often of a much lower standard
(Ishihara, Kikuchi and Sandberg, 1963; Sandberg et al., 1962; Nowell and
Hungerford, 1964).
It is apparent that the permutations of the 17,18 chromosomes whichhave
been observed in neoplastic cells are very numerous: they exceed in variety the
reported anomalies of any other chromosome or group. Morphologically indis-
tinguishable though not necessarily identical aberrations have in some instances
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been described as constitutional chromosomal anomalies and these will be men-
tioned in the following review of the published data.
Normal complement of 17,18 chromosomes (A in Fig. 1)
This configuration is not a rarity in tumour cells. Obviously, visible anomaly
of the group 17,18 chromosomes is neither a prerequisite for the occurrence of
neoplasms in general, nor their invariable sequel. Furthermore, there is no single
histological category of tumours in which anomalies of the 17,18 chromosomes are
a constant feature.
A.AAAA NORMAL = 4E
B.XX,XX Long,-arm Isochromosome.
C ASA Monosomy =3E.
D.AAAA 3E+Short-arm deletion (=Ep-).
E.AAAAA4E+Ep-.
F.,)AAAAA3E+2(Ep-).
G.AAAAATrisomy =5E.
H.AXA X 3E+Loni-arm deletion (=Eq-).
I.AAAAX 4E+Eq-.
J.A AXx X 3E+2(Eq.-).
K. AAAA 3E+?Extra G.
L.AA A A 2E+? 2 Extra G.
M.AAAX ? Translocation to shortarms.
FIG. 1. Configurations of the group 17,18 (E group) chromosomes observed in tumour cells.
Long-arm isochromosome (B in Fig. 1)
A metacentric chromosome larger than a No. 16 may replace one normal
member of the group 17,18. This anomaly, which seems likely to be an iso-
chromosome for the long arm ofa 17,18 chromosome, hasbeenobservedinHodgkin's
tissue (Ricci et al., 1962), reticulum cell sarcoma (Sasaki, Sofuni and Makino,
1965), in peripheral blood culture in chronic lymphocytic leukaemia (Fitzgerald
and Adams, 1965), and in no less than 13 cases of chronic granulocytic leukaemia
at the stage ofmetamorphosis (Engel et al., 1965; Stich et al., 1966; Engel, McKee
and Bunting, 1967; de Grouchy et al., 1968). The anomaly has also been described
in myelosclerosis after transformation to acute granulocytic leukaemia (Nowell
and Hungerford, 1962), and in a myeloproliferative disorder characterized by
anaemia, thrombocytopenia, and maturation arrest in the bone marrow (Engel
McKee and Bunting, 1967). A similar isochromosome, at that time unrecognized,
appears to have been present in cultured and uncultured lymph node cells from a
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case of lymphosarcoma described by us in an earlier report (Spiers and Baikie,
1968a).
Recent work by de Grouchy and his colleagues (1968) suggests that acquisition
ofan isochromosome for a member ofthe group 17,18 may be ofspecial importance
in the evolution ofnew cell lines during the metamorphosis of chronic granulocytic
leukaemia. The configuration (B) of Fig. 1 was observed in Ph'-positive cells
from 11 of 24 cases of chronic granulocytic leukaemia: the authors considered the
metacentric element to be an isochromosome for the long arms of a No. 17 chro-
mosome. Minor cell lines were also present, each occurring in several cases: in
one such line the isochromosome was extra to a full complement of normal 17,18
chromosomes, and another line showed loss of a No. 17 without possessing the
isochromosome, i.e. the configuration represented by (C) in Fig. 1.
An apparent isochromosome for the long arms of a group 17,18 member has
been observed as a constitutional abnormality in a child with multiple congenital
defects but no evidence of neoplasm (Armendares, Frank, Trevino and Sanchez,
1966, personal communication).
Monosomy of a group 17,18 chromosome (C in Fig. 1)
Consistent loss of a 17,18 chromosome from the tumour cells has been reported
in 5 cases of Hodgkin's disease (Miles, Geller and O'Neill, 1966; Sinks and Clein,
1966), 3 cases of reticulum cell sarcoma (Spiers and Baikie, 1968a; Miles, Geller
and O'Neill, 1966; Lawler, Pentycross and Reeves, 1968), and a case of lympho-
sarcoma (Spiers and Baikie, 1968a). A 17,18 monosomy has been described in at
least 7 cases of chronic granulocytic leukaemia after metamorphosis (Court
Brown and Tough, 1963; Pedersen, 1964; de Grouchy et al., 1966; Spiers and
Baikie, 1968b). Pedersen (1967) finds that in chronic granulocytic leukaemia,
Ph'-positive cells with monosomy in the group 17,18 occur more commonly in
patients who have recently received treatment for their disease. That treatment
favours a relative increase in such cells would be compatible with the view that
the additional chromosomal lesion confers a survival advantage, presumably in
the form of increased resistance to drugs and X-irradiation. Monosomy of a
group 17,18 chromosome has also been reported in a case described as one of
polycythaemia having undergone conversion to myelosclerosis (Nowell andHunger-
ford, 1962), and was a consistent feature ofthe karyotypes from a medulloblastoma
(Lubs, Salmon and Flanigan, 1966). In this latter case, an isochromosome for the
long arms of the missing chromosome may have been present, making a total of
20 instances of anomaly (B) of Fig. 1 in association with neoplasia.
Complete monosomy of a group 17,18 chromosome has not been reported as a
constitutional anomaly, but in a case of probably XX/XY lymphoid chimaerism
the bone marrow shortly before death contained a cell-line lacking a group 17, 18
chromosome and having a staining reaction which the authors associated with
acute leukaemia (Kadowaki et al., 1965). No other evidence of neoplastic change
was found in this remarkable case.
Short-arm deletion of one group 17,18 chromosome (D in Fig. 1)
The short arm ofa 17,18 chromosome, probably a No. 18, has undergone almost
complete deletion, producing a highly acrocentric chromosome. This anomaly
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was originally described in 2 cases of Hodgkin's disease and a case of follicular
lymphoma (Spiers and Baikie, 1966, 1968a). The abnormal chromosome was
present only in tissue from neoplastic lymph nodes and was absent from cultures
of peripheral blood lymphocytes, thus appearing to be an acquired anomaly
peculiar to the lymphoma tissue. The deleted chromosome was frequently
observed in metaphases without other chromosomal anomalies: there is reason to
believe that these metaphases were those of tumour cells, since they occurred in
large numbers in 20-hour cultures to which no mitotic stimulator had been added.
The abnormal group 17,18 member was named the Melbourne chromosome (MI)
in accordance with the recommendations of the Denver conference (Human
Chromosomes Study Group, 1960), reserving the term for the chromosomal lesion
occurring in association with malignant lymphoma (Baikie and Spiers, 1966).
This anomaly is now described as Ep-, or possibly 18p-, following the new recom-
mendations of the Chicago conference (Chicago Conference, 1966). This unusual
lesion has since been observed in a case of reticulum cell sarcoma (Millard and Seif,
1967; Millard, 1968) and in another patient with reticulum cell sarcoma of familial
occurrence (Kajii, Neu and Gardner, 1968). In the latter case, metaphases from
peripheral blood culture showed no abnormality, so the deleted group 17,18
chromosome appeared to be an acquired, not an inherited, anomaly, associated with
the neoplastic lymph node tissue. A similar abnormal chromosome may have
been present in another reticulum cell sarcoma (Case 12 of Miles, Geller and
O'Neill, 1966). One ofthe normal E group chromosomes was missing from tumour
cell metaphases and a constant small marker was present. This was described as
about the size of a No. 12 chromosome but having very small short arms: unfortu-
nately the abnormal chromosome was not illustrated, but it may have been an
Ep-. The Ep- chromosome may thus have been observed in as many as 6 cases
of malignant lymphoma, while there are no reports of a 17,18 chromosome with
deleted short arms occurring as an acquired lesion in any other situation.
However, a morphologically similar chromosome, considered to be a No. 18
with deleted short arms, has been described as a constitutional anomaly in at least
14 individuals (de Grouchy etal., 1963; Lewis, Poulding and Woods, 1963, personal
communication; Biihler, Buhler and Stadler, 1964; Summit, 1964; Van Dyke,
Valdmanis and Mann, 1964; Hickox, 1964; Edwards, 1964, personal communica-
tion; Uchida etal., 1965; Jacobsen, 1966). A partial loss of the short-arm material
has also been described (Dill and Miller, 1963, personal communication), and 4
cases have been reported in which the short arms of a No. 18 chromosome have
been lost or translocated with formation of a ring chromosome (Wang et al., 1962;
Genest, Leclerc and Auger, 1963; de Grouchy, 1965). All these individuals showed
mental retardation and other congenital defects, but none has been reported as
developing malignant lymphoma or other neoplasm.
Ep-chromosomer and 4 normal group 17,18 members (E in Fig. 1)
The combination of an Ep- chromosome together with a full complement of
normal 17,18 chromosomes is an unusual cytogenetic situation. This has been
observed in the predominant cell line cultured from a lymph node involved by
follicular lymphoma (Spiers and Baikie, 1966, 1968a). Cell lines showing the
combinations represented by (D) and (F) of Fig. were also present in this node,
in relatively small numbers.
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Two Ep- chromosomes and 3 normal group 17,18 members (F in Fig. 1)
This chromosomal constitution appears to have been observed only in the case
of follicular lymphoma referred to above.
Gain of a group 17,18 chromosome (G in Fig. 1)
A trisomic condition of one of the group 17,18 chromosomes has been reported
in 3 cases oflymphosarcoma (Sandberg et al., 1964), amixedlymphoblast-reticulum
cell lymphoma (Millard, 1968), and 4 cases of reticulum cell sarcoma (Lawler,
Pentycross and Reeves, 1968; Miles, 1967). This anomaly has also been described
in 6 out of 16 cases of primary macroglobulinaemia (Tanzer et al., 1966), and in a
case of chronic granulocytic leukaemia after metamorphosis (Spiers and Baikie,
1968b).
Constitutional trisomy of a group 17,18 chromosome, probably No. 18, is well
recognized (Hecht et al., 1963; de Grouchy, 1965), and is attended by multiple
congenital anomalies. Neoplasia has not been described in these patients, but
because of their malformations survival is short, so it must be uncertain whether
they have any special liability to develop malignant tumours.
Long-arm deletion of one group 17,18 chromosome (H in Fig. 1)
This cytogenetic situation appears quite different from those previously de-
scribed. Part of the long arms of a group 17,18 chromosome, thought to be a
No. 18, has undergone deletion. The anomaly was originally described by Millard
and Seif (1967) in London and Oxford and has since been reported elsewhere
(Engel, McKee and Bunting, 1967) and described more fully by Millard (1968).
This lesion has been observed in 2 cases of Hodgkin's disease (Seif and Spriggs,
1967) and 5 cases of other malignant lymphoma (Millard, 1968; Dartnall and
Baikie, unpublished observations). Partial deletion of the long arms of a group
17,18 chromosome has also been found in tumour cell metaphases from a case of
acute promyelocytic leukaemia (Engel, McKee and Bunting, 1967) and 2 Phl-
positive cases ofchronic granulocytic leukaemia (Kiossoglou, Mitus and Dameshek,
1965; Lam-Po-Tang, 1967, personal communication). The same anomaly may also
be present (Millard, 1967, personal communication) in metaphases obtained from
a case of follicular lymphoma described in a previous report (Case 1 of Spiers and
Baikie, 1968a). In accordance with current practice (Chicago Conference, 1966),
this chromosomal lesion is designated Eq-, or possibly 18q-.
A morphologically similar deletion of about half the long arms of chromosome
18 has been observed as a constitutional anomaly in 2 patients with congenital
abnormalities (de Grouchy, 1965). Unfortunately, the term 18q- is lacking in
specificity, for it fails to distinguish between the anomaly in its acquired and
congenital forms, which may be structurally and functionally quite different.
Eq- chromosome and 4 normal group 17,18 members (I in Fig. 1)
The combination of an Eq- chromosome and a full complement of morpholo-
gically normal group 17,18 chromosomes occurred in Case 3 of Millard (1968).
Cells with this anomaly are partially trisomic for a group 17,18 chromosome. An
apparently similar chromosomal complement has been described as a constitutional
anomaly in 1 case (Crawford, 1961), but constitutional trisomy for part of a 17,18
82CHROMOSOMES IN RETICULOENDOTHELIAL NEOPLASIA
chromosome has usually been associated with unbalanced translocation (Ilbery
and Alexander, 1967).
Two Eq- chromosomes and 3 normal group 17,18 members (J in Fig. 1)
Apparent loss of one of the normal group 17,18 chromosomes and presence of
2 Eq- chromosomes was seen in some cells of Case 3 of Millard (1968). This case
had cell lines with anomalies ofthe types (H), (I) and (J) ofFig. 1, cells with type
(I) being the most numerous. The situation is in some ways analogous to that
referred to above (Subheading: Ep- chromosome and 4 normal group 17,18
members), where tumour tissue was described containing cell lines of types (ID),
(E) and (F), with type (E) predominating. In each of these 2 cases, the cell line
with no monosomy for part of a 17,18 member (i.e. the abnormal element, Ep- or
Eq-, was an extra chromosome), was most numerous in the tumour cell population.
Loss ofa group 17,18 chromosome andpresence ofan acrocentric element (K inFig. 1)
This chromosomal constitution was observed in a reticulum cell lymphoma with
a follicular pattern (Case 12 of Millard, 1968). One possible interpretation is loss
of a group 17,18 chromosome and acquisition of an extra G group chromosome:
both events might be the result of mitotic nondisjunction. However, as the two
changes were not seen apart from one another and preserved an apparently strict
numerical relationship (vide infra), it may also be postulated that the small
acrocentric chromosome is in fact the missing group 17,18 member, which has lost
a major portion of its long arms and part of its short arms, to produce an element
indistinguishable from the chromosomes of group G. If this is so, the abnormal
chromosome would be designated Ep-q-. It was noted, however, that this
chromosome was sometimes larger than the members of group G. Since only a
slight difference in the lengths of the long arms distinguishes Ep-q- from the
original M1 chromosome (Ep-), it is not impossible thatthesearethesamestructure:
the quality ofthe preparations did not permit a firm decision on this point (Millard,
1969, personal communication). Even moderate degrees of chromosomal contrac-
tion due to demecolcine cause the Ep- chromosome to resemble the chromosomes
of group G (Spiers and Baikie, 1968a). An element which resembles the Ep-q-
anomaly was observed in a case oflymphosarcoma (Tjio et al., 1963), but might be
a No. 15 chromosome with partially deleted long arms.
Two group 17,18 chromosomes and two acrocentric elements (L in Fig. 1)
This arrangement was observed in the same case as anomaly (K) of Fig. 1.
Tumour cell metaphases which appeared to have lost 2 of the normal group 17,18
chromosomes always appeared to have acquired 2 extra small acrocentric elements.
This numerical relationship must make it more probable that the extra acrocentric
elements in arrangements (K) and (L) of Fig. 1 are in fact altered group 17,18
chromosomes.
Large short arms in a group 17,18 chromosome (M in Fig. 1)
This aberration was reported in a case described as one of di Guglielmo syn-
drome with terminal acute granulocytic leukaemia (Engel, McKee and Bunting,
1967). The abnormal element which replaces one ofthe group 17,18 chromosomes
is not metacentric and thus cannot be regarded as an isochromosome. The
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authors considered that extra material had become translocated on to the short
arms of a No. 18 chromosome, though other explanations are of course possible.
In the above review, it is notable that reports seeming to connect aberrations
of the group 17,18 chromosomes with neoplasia show a preponderance of non-
epithelial tumours, particularly malignant lymphomas and leukaemias. This may
in part be due to relatively more numerous cytogenetic investigations of these
disorders, but also suggests that the group 17,18 members may carry genetic
material which has special relevance to the activities of lymphoid and reticulo-
endothelial tissues. In this connection it is of great interest that several recent
reports show an apparent association between congenital deletions ofchromosome
No. 18 and defects of immunoglobulin (IgA) production and/or secretion (Finley
et al., 1968; Richards and Hobbs, 1968; Warren, 1968; Stewart et al., 1968;
Feingold et al., 1968). Failure to demonstrate immunoglobulin disturbances in
association with several other types of congenital chromosomal deletion (Feingold
and Schwartz, 1968) suggests that the effect is not a non-specific one, and must
lend further support to the view that genes carried by chromosome No. 18 are
concerned in the regulation of lymphoid cells.
DISCUSSION
About 4 years ago it was suggested (Spiers and Baikie, 1966) from the evidence
then available, that the group 17,18 chromosomes might have some special
association with lymphoid neoplasia. Since then, further evidence has come from
several laboratories which tends to support this hypothesis. Certainly, acquired
lesions of these chromosomes have frequently been observed in tumour cells,
particularly in the malignant lymphomas. Furthermore, despite continuing
cytogenetic research, similar acquired lesions of the group 17,18 chromosomes
have not been described in non-neoplastic disorders. Anomalies of the group
17,18 and other chromosomes have however been demonstrated in normal human
cells infected in vitro with the SV40 virus, which is oncogenic in some animal
species (Moorhead and Saksela, 1963). It is of interest that karyotypic changes
closely resembling those produced by SV40 virus have been observed in a human
reticulum cell sarcoma, where monosomy of a No. 18 chromosome was accom-
panied by the presence of abnormal secondary constrictions in the remaining
No. 18 and in chromosomes Nos. 1 and 9 (Spiers and Baikie, 1967).
Gofman and his colleagues (1967) have recently presented evidence obtained
from the study of5 human cancers which suggests a special role forthe chromosome
pair 16 in the natural history of tumours. However, 3 of the tumours studied
were established cell lines which had been maintained in prolonged culture in vitro.
The validity of the conclusion drawn must at present be in doubt, since there is a
very real possibility that misleading selection had occurred in these long-term
cultures.
Unfortunately, most of the data so far presented in the literature are quite
unsuitable for a formal statistical analysis to decide whether anomalies of the
17,18 chromosomes occur in tumours with a frequency greater than might be due
to chance. Since these chromosomes occupy a relatively peripheral position in
metaphases prepared by the usual techniques (Miller, Breg et al., 1963), and may
occupy a similar position on the mitotic spindle in vivo, it might be argued thatthe
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17,18 chromosomes are specially prone to undergo random numerical changes as a
result of either mitotic accidents or the methods of preparing cells for study.
Such changes would be irrelevant to cancer. However, both the Ychromosome
(Miller, Mukherjee et al., 1963), and the heterochromatic X chromosome (Barton,
David and Merrington, 1964) occupy similarly peripheral positions and relatively
seldom show aberrations in neoplastic cells. A rare exception to this is the
occasional loss of the Y chromosome from the tumour cells in chronic granulocytic
leukaemia (Speed and Lawler, 1964).
The studies of Kerkis, Radzhabli, Pospelova and Viisotaskoya (1966, personal
communication) of the chromosomes involved in the increasing aneuploidy known
to occur in human leucocytes with advancing age provide some evidence of the
changes that a random process might produce. The loss of chromosomes appeared
to be related to their position at metaphase, and the group 17,18 members were
quite frequently affected. However, gain of extra group 17,18 chromosomes was
not seen and the increase in aneuploidy was in the direction of hypodiploidy. In
tumour cells, with the possible exception of the hypotetraploid forms seen in
later stages of neoplasia, the gain of extra group 17,18 chromosomes is about as
common as loss. Thus it seems most unlikely that either the frequency or the
nature of the numerical aberrations of these chromosomes observed in cancer cells
is attributable solely to their position on the mitotic spindle.
It has also been argued that many of the chromosome losses and gains seen in
cancer cells are completely random results ofmitotic accidents, without any special
reference to the position of chromosomes on the mitotic spindle. If this were the
case, changes should affect the group 6-12 members, 14 in number, more than
three times oftener than the group 17,18 chromosomes, of which there are only 4.
This is certainly not the case in the large number of malignant lymphomas and
related neoplasms which has been studied. In chronic granulocytic leukaemia,
numerical changes affecting the chromosomes of the group 17,18 are in fact 6
times more common than changes affecting the chromosomes of group 6-12
(Pedersen, 1969). Finally, the relatively frequent structural rearrangements of
group 17,18 chromosomes which have been described (Fig. 1), most of them in
several individuals, cannot be explained by mitotic errors. It is exceedingly
difficult to attribute these structural anomalies to chance alone, particularly as
none of these abnormalities has been observed as an acquired lesion in non-
neoplastic tissues. Little doubt can remain that the group 17,18 chromosomes
do indeed have some special role in reticuloendothelial neoplasia. The possible
nature of this role will next be considered.
Changes in the group 17,18 chromosomes may be of aetiological significance
Some at least ofthe changes observed may result from the action of a chemical
substance, virus, or other carcinogen and may be the first step in the neoplastic
process. It is at present impossible to decide on this point, since in no case do
we know the temporal relations between development ofthe chromosomal anomaly
and the appearance of neoplasia. Prospective studies aimed at demonstrating a
chromosomal lesion in individuals who subsequently develop lymphoma or other
neoplasm are scarcely feasible, because repeated biopsies in normal subjects are
unacceptable and there is no known high-risk group which might profitably be
studied. Of the anomalies we have described (Fig. 1), the Ep- and Eq- chromo-
somes might stand the best chance of possessing causal significance, since both are
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uncommon lesions which cannot be the result of simple mitotic non-disjunction
and each may be seen in lymphoma cells without other karyotypic abnormality.
That the Ep- and Eq- anomalies occur in relatively few cases of lymphoma in
no way excludes the possibility of their possessing aetiological significance: to
apply Koch's postulates to oncogenesis is surely inappropriate. It is hardly to be
expected that there should be but a single cytogenetic pathway by which neoplastic
status may be reached, even by cells having the same differentiation. A single
pathway is even less probable for cells of unlike differentiation. As has been
pointed out, most of the anomalies of the group 17,18 chromosomes which occur
in tumour cells have also been reported in occasional cases as constitutional
chromosomal abnormalities. Although these constitutional aberrations have not
been associated with lymphoma or other tumours, this is not a serious argument
against a possible role of the acquired form of the anomaly in tumorigenesis. It
is possible that the constitutional defect, although on light microscopy morpho-
logically similar to the acquired lesion, is quite different as regards gene constitu-
tion. For example, in the constitutional lesion, the apparently deleted chromo-
somal material may still be present in the cell, translocated onto one of the larger
chromosomes and undetectable by ordinary methods of observation. In its new
position it may exert genetic effects different from the normal. On the other
hand, in the acquired lesion this material may be genuinely lost from the cell.
Even ifthe congenital and the acquired chromosomal anomalies are in fact identical,
in the constitutional disorder the anomaly is present in all, or most, of the body
cells, and has been present from birth. In the acquired disorders, neither of these
considerations applies, and this difference is very profound in itself. Furthermore,
the small numbers of individuals possessing the various anomalies in their con-
stitutional form, coupled with their usually short survival due to multiple con-
genital defects, may have prevented the observation of cancer in any of them.
Thus the possibility cannot be excluded that lesions of the group 17,18 chro-
mosomes, particularly the finer structural alterations such as partial deletions, may
have an aetiological role in some tumours.
Alterations in the group 17,18 chromosomes may be secondary to neoplasia and
irrelevant to either the inception or the progression of tumours
It has been shown that both the frequency and the nature of the abnormalities
of group 17,18 chromosomes observed in cancer cells makes them unlikely to be
due to chance-alone. While accepting the proposition that cytogenetic changes
which are both secondary to neoplasia and also irrelevant to its further evolution
may not depend solely on chance for their occurrence, it seems likely that they will
usually be random events. Chromosomal changes which have no bearing on the
activity of the tumour in which they arise will tend to be even more diverse than
the observed permutations of the 17,18 group, since they will not be liable to the
effects of natural selection. However, they are unlikely to be reproduced con-
sistently in many cell generations, and so each anomaly will be found in only afew
karyotypes. Such apparently haphazard changes do in fact occur in the karyo-
types of some carcinoma cells (Spriggs, Boddington and Clarke, 1962; Ishihara,
Kikuchi and Sandberg, 1963). However, alterations of the 17,18 group described
in lymphoma (Spiers and Baikie, 1968a; Millard, 1968) and leukaemia (Engel,
McKee and Bunting, 1967; Spiers and Baikie, 1968b) are remarkably consistent,
sometimes occurring in every metaphase from a particular tumour. In such
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circumstances, the changes observed may well be secondary to the onset of
neoplasia, but the view that they are irrelevant to the biology of the neoplastic
cells is scarcely tenable.
Anomalies of the group 17,18 chromosomes nmay be secondary phenomena which
nevertheless are of evolutionary significancefor tumour cells
While maintaining the view that some of the anomalies observed, particularly
the Ep- and Eq- chromosomes, may be primary changes linked to the inception of
neoplasia, it seems very probably that some permutations of the 17,18 group are
concerned with tumour cell evolution. These changes presumably arise after
neoplasia is established, and thus cannot be its cause, but they do influence the
subsequent behaviour of the tumour cells in which they occur. This may be the
case with various numerical changes, which are seen to affect both normal and
structurally anomalous members ofthe group (Fig. 1). Thus it appears that loss
ofa group 17,18 chromosome may favour cellproliferation, as cellsofthiskaryotype
(C in Fig. 1), are quite often the dominant line in the tumours in which they occur
(Spiers and Baikie, 1968a, b). Structural modifications also may confer a growth
TABLE I.-Occurrence ofSome Structural Anomalies of the Group 17,18
Chromosonmes in Neoplastic Cells
Disease
Hodgkin's disease
Reticulum cell sarcoma
Lymphosarcoma
Chronic lymphocytic
leukaemia
Chronic granulocytic
leukaemia in
metamorphosis
Acute granulocytic
leukaemia
D. 3E + Ep- Hodgkin's disease
Follicular lymphoma
Reticulum cell sarcoma
H. 3E + Eq- . Hodgkin's disease
Follicular lymphoma
Other lymphoma
Acute promyelocytic
leukaemia
Chronic granulocytic
leukaemia
M. Translocation to
short arms,
3E + Ep+
. Di Guglielmo syndrome.
No.
cases
with
anomaly
1
1
1
1
11
1
1
1
2
1
1
1
2
4
Total no.
of cases
y examined*
1
2
4
28
24
1
1
2
1
5
6
3
1
4
8
6
12
Authors
Ricci et al., 1962
Sasaki et al., 1965
Spiers and Baikie, 1968
Fitzgerald and Adams, 1965
de Grouchy et al., 1968
Engel et al., 1967
Stich et al., 1966
Nowell and Hungerford, 1962
Engel et al., 1967
Spiers and Baikie, 1968
Spiers and Baikie, 1968
Millard, 1968
Kajii et al., 1968
Miles et al., 1966
Seif and Spriggs, 1967
Spiers and Baikie, 1968
Millard, 1968
I . 1 . Engel et al., 1967
1 2 Lam-Po-Tang, 1967,
personal communication
1 2 . Kiossoglou et al., 1965
1 . 1 . Engel et al., 1967
* As some communications report single cases, the total number examined is sometimes uncertain.
Chromosomal
anomaly
B. Long-arm
isochromosome
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advantage, and consequent survival advantage, upon tumour cells. The replace-
ment of 1 normal member ofthe group 17,18 by an Ep- chromosome (D in Fig. 1),
or by a long-arm isochromosome (B in Fig. 1), results in the cell becoming mono-
somic for the short-arm material ofthe chromosome which has been replaced. In
the case of isochromosome formation, the cell also becomes trisomic for the long-
arm material (Table II).
Both situations appear favourable for excessive cell multiplication. In
chronic granulocytic leukaemia, there is very strong evidence that the formation
of an isochromosome for the long arms of a No. 17 chromosome is a secondary
phenomenon but relevant to the further evolution of the neoplasm. Thus, in the
early stages of the disease, the Ph' chromosome is the only anomaly present,
whilst after the occurrence of metamorphosis to a more anaplastic neoplasm, the
isochromosome 17 is observed in a surprisingly high proportion of cases (de
Grouchy et al., 1968). When a lymphoma cell apparently loses one No. 17,18
chromosome and acquires 2 Ep- chromosomes (F in Fig. 1), the situationresembles
that in cells possessing a long-arm isochromosome, i.e. there is a short-arm mono-
somy and a long-arm trisomy (Table II). In another permutation, (E in Fig. 1),
4 normal group 17,18 chromosomes are retained, and the Ep- is an extra chromo-
some. In this case there is a long-arm trisomy without any short-arm monosomy,
a situation which may be particularly advantageous, since cells ofthis constitution
have been observed as the dominant element in a tumour cell population which
also contained representatives ofcell types (D) and (F) ofFig. 1 (Spiers and Baikie,
1966, 1968a).
Paradoxically, gain of a group 17,18 chromosome to produce a fully trisomic
condition (G in Fig. 1), seems to be as favourable for cell proliferation as the
monosomic or partially monosomic conditions discussed earlier. However, it is
possible to formulate an hypothesis which can account for these facts while retain-
ing a reasonable economy of assumptions.
Suppose that the short arms of the affected group 17,18 chromosome carry
genes which normally retard cell multiplication, whereas some of the genes on the
long arms promote multiplication. Any cytogenetic change which alters the
normal 1: 1 ratio of short-arm to long-arm material in favour of the latter, e.g.
changes of types (B), (D), (E) or (F) of Fig. 1, will favour cell division, perhaps in
an uncontrolled fashion. As may be seen from Table II, in (B), (D), (E) and (F)
the short-arm: long-arm ratios for the involved pair, either 17 or 18, are 1: 3,
1: 2, 2: 3 and 1: 3, respectively. It was earlier pointed out that situation (E),
where there is long-arm trisomy without short-arm monosomy, may be particularly
advantageous for cell growth and survival, as cells of this constitution appear to
TABLE II.-Relative Amounts of Long-arm and Short-arm Material of the
Affected Chromosome Pair in Some of the Group 17,18 Anomalies
Depicted in Fig. 1
Short-arm material Long-arm material
Anomaly (SA) (LA) SA: LA Ratio
A Disomic Disomic . 1 1
B Monosomic . Trisomic 1: 3
C . Monosomic . Monosomic . 1 1
D . Monosomic . Disomic . 1: 2
E Disomic . Trisomic 2: 3
F Monosomic Trisomic 1: 3
G . Trisomic Trisomic 1 1
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compete successfully with cells which do show a short-arm monosomy. This is
readily accounted for by the very reasonable assumption that some ofthe genetic
material on the short arms is of importance in cell metabolism and operates more
effectively when in the disomic state. Such type (E) cells will possess an excess
of " proliferative " genes due to their long-arm trisomy while having a more
efficient metabolism than, say, type (D) cells because no important genetic material
is missing from the cell.
The above hypothesis does not, ofcourse, by itselfexplain whythe chromosomal
constitutions (C) and (G) of Fig. 1 might favour cell multiplication, since in each
situation the short-arm: long-arm ratio is 1: 1 as in normal cells (Table II).
Since gene-dose effects do not always follow the principles of simple arithmetic, it
could be postulated that the " anti-proliferative " genes on the short arms are
virtually ineffective when monosomic, whilst their effect is not augmented above
the normal by becoming trisomic. If the " proliferative " genes on the long
arms were subject to no such limitation, the effective short-arm: long-arm ratios
in (C) and (G) type cells would be 0: 1 and 2: 3 respectively. Because of
insufficient evidence, this view is merely a speculation, and in fact, a simpler
explanation is available. On reviewing those cases of malignant lymphoma
(Sandberg et al., 1964; Miles, Geller and O'Neill, 1966; Sinks and Clein, 1966;
Miles, 1967; Millard, 1968; Spiers and Baikie, 1968a) and leukaemia (Court Brown
and Tough, 1963; Pedersen, 1964; de Grouchy et al., 1966; Spiers and Baikie,
1968b) in which cells of types (C) and (G) have been observed, it was found that
changes in other chromosomal groups were usually present. These changes were
often multiple and complex and sometimes included the possession of 1 or more
Ph' chromosomes. By contrast, the Ep- chromosomal anomaly commonly
occurs in cells whose chromosomal constitution is otherwise normal or nearly so.
Thus the effects of trisomy or monosomy of a group 17,18 chromosome may be
less important, and possibly mediated in a quite different way, to the effects of
structural anomalies ofthese chromosomes, since the 2 types of aberration seem to
occur in cells whose other genetic components are very different.
The foregoing arguments cannot apply to the Eq- chromosome described by
Millard (1968) and by Seif and Spriggs (1967), since here the deletion involves the
long arms of a group 17,18 chromosome, probably No. 18. The Eq- chromosome
has been observed as an extra element (I) and also in place of one of the normal
chromosomes of the group (H in Fig. 1). If this change is of evolutionary signi-
ficance for the neoplastic cells, which seems probable, it may be necessary to
postulate other inhibitory or regulatory genes, located on the distal part of the
long arm of No. 18, whose loss favours cell growth. A similar situation may well
obtain in chromosome 21, where formation of the Ph1, by deletion of part of the
long arms, clearly favours cell proliferation.
The objection may be raised that all the above suggestions are based on re-
latively slender evidence and that they invest the group 17,18 chromosomes with
complex structural and functional attributes. This is quite true. On the other
hand, there is sufficient evidence which seems to implicate these chromosomes in
the genesis and/or evolution of some malignant neoplasms to warrant a tentative
hypothesis to explain the facts. Such an hypothesis might serve as a basis for
further and better studies leading to its modification or rejection. The com-
plexity of the hypothesis is unfortunate but accords well with the habitual com-
plexity of biological systems in general and of cancer in particular.
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